Patents Assigned to Karl-Franzens-Universität Graz
-
Publication number: 20220289698Abstract: The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.Type: ApplicationFiled: July 30, 2020Publication date: September 15, 2022Applicants: Karl-Franzens-Universität Graz, Technische Universität GrazInventors: Gernot GRABNER, Rudolf ZECHNER, Robert ZIMMERMANN, Rolf BREINBAUER, Anna MIGGLAUTSCH, Nikolaus GUTTENBERGER
-
Patent number: 10954255Abstract: The present invention relates to a compound having a structure according to formula (I) or a salt thereof, wherein: R1 is a branched or linear alkyl, acyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, or hydroxy-alkinyl residue comprising 6 to 30 carbon atoms, R2 is selected from the group consisting of: a) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal or cyclic quaternary ammonium, b) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal amino group and/or 1 to 3 hydroxyl groups, c) an amino acid residue, d) a five or six carbon sugar and e) H, R3 is a residue selected from the group consisting of an alkyl, alkenyl, prostanyl-dialkyl, furanyl-dialkyl, cyclobutyl-dialkyl, cycloalkyl and aryl group of 2 to 40 carbon atoms length and comprising at least one keto group, epoxy group, aldehyde group, peroxy group, hydroperoxy group, hydroxyl group or a free carboxyl group, L1 is selected from the group consisting of O, NH, S, CH2, (aa), (bb), (cc), (dd), (ee), (ff), (gg)Type: GrantFiled: July 27, 2018Date of Patent: March 23, 2021Assignees: Karl-Franzens-Universitaet Graz, University of ChicagoInventors: Konstantin Birukov, Anna Birukova, Valery Bochkov, Olga Oskolkova
-
Patent number: 10929967Abstract: Method for processing of a grey scale image, in particular a dim grey scale image, comprising the following steps: a) receiving an initial grey scale image, said initial grey scale image having a plurality of pixels at an initial resolution, b) calculating parameters characterizing the luminance (gain, median_grey, var_grey) and the noise level (X, noise_estimate, radius_spatial_summation, grid_size, threshold_var) of the initial grey scale image of step a), c) creating a basic intermediate image, d) creating an averaged intermediate image, and e) creating an enhanced grey scale image by interpolation of pixels based on the averaged receptors (greyAvg) of the averaged intermediate image of step d).Type: GrantFiled: December 15, 2017Date of Patent: February 23, 2021Assignee: KARL-FRANZENS-UNIVERSITÄT GRAZInventor: Manfred Hartbauer
-
Publication number: 20200157127Abstract: The present invention relates to a compound having a structure according to formula (I) or a salt thereof, wherein: R1 is a branched or linear alkyl, acyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, or hydroxy-alkinyl residue comprising 6 to 30 carbon atoms, R2 is selected from the group consisting of: a) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal or cyclic quaternary ammonium, b) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal amino group and/or 1 to 3 hydroxyl groups, c) an amino acid residue, d) a five or six carbon sugar and e) H, R3 is a residue selected from the group consisting of an alkyl, alkenyl, prostanyl-dialkyl, furanyl-dialkyl, cyclobutyl-dialkyl, cycloalkyl and aryl group of 2 to 40 carbon atoms length and comprising at least one keto group, epoxy group, aldehyde group, peroxy group, hydroperoxy group, hydroxyl group or a free carboxyl group, L1 is selected from the group consisting of O, NH, S, CH2, (aa), (bb), (cc), (dd), (ee), (ff), (gg)Type: ApplicationFiled: July 27, 2018Publication date: May 21, 2020Applicants: Karl-Franzens-Universitaet Graz, University of ChicagoInventors: Konstantin Birukov, Anna Birukova, Valery Bochkov, Olga Oskolkova
-
Patent number: 9206115Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.Type: GrantFiled: January 23, 2014Date of Patent: December 8, 2015Assignees: Technische Universität Graz, Karl-Franzens-Universität GrazInventors: Martina Schweiger, Matthias Romauch, Robert Zimmermann, Nicole Mayer, Rolf Breinbauer
-
Publication number: 20140206738Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.Type: ApplicationFiled: January 23, 2014Publication date: July 24, 2014Applicants: Karl-Franzens-Universität Graz, Technische Universität GrazInventors: Martina SCHWEIGER, Matthias ROMAUCH, Robert ZIMMERMANN, Nicole MAYER, Rolf BREINBAUER